Biontech SE
BNTX99.850USD
+1.000+1.01%
Close 01/09, 16:00（ET）Quotes delayed by 15 min
24.01BMarket Cap
LossP/E TTM
More Details of Biontech SE Company
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Biontech SE Info
Ticker SymbolBNTX
Company nameBiontech SE
IPO dateOct 10, 2019
CEOSahin (Ugur)
Number of employees6772
Security typeDepository Receipt
Fiscal year-endOct 10
AddressAn der Goldgrube 12
CityMAINZ
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryGermany
Postal code55131
Phone4949613190840
Websitehttps://www.biontech.com/
Ticker SymbolBNTX
IPO dateOct 10, 2019
CEOSahin (Ugur)
Company Executives of Biontech SE
Name
Name/Position
Position
Shareholding
Change
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+12755.00%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
+790.00%
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Prof. Ugur Sahin, M.D.
Prof. Ugur Sahin, M.D.
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Oezlem Tuereci, M.D.
Dr. Oezlem Tuereci, M.D.
Chief Medical Office, Member of the Management Board
Chief Medical Office, Member of the Management Board
--
--
Mr. Helmut Jeggle
Mr. Helmut Jeggle
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
Mr. Michael Motschmann
Mr. Michael Motschmann
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Mr. Michael Horowicz
Mr. Michael Horowicz
Director, Investor Relations
Director, Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+12755.00%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
+790.00%
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Prof. Ugur Sahin, M.D.
Prof. Ugur Sahin, M.D.
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Revenue Breakdown
Currency: USDUpdated: Wed, Mar 12
Currency: USDUpdated: Wed, Mar 12
FY2019
FY2018
FY2017
By BusinessUSD
Name
Revenue
Proportion
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
AT Impf GmbH
39.32%
Medine GmbH
15.49%
Baillie Gifford & Co.
3.04%
Fidelity Management & Research Company LLC
1.92%
T. Rowe Price Investment Management, Inc.
1.87%
Other
38.36%
Shareholders
Shareholders
Proportion
AT Impf GmbH
39.32%
Medine GmbH
15.49%
Baillie Gifford & Co.
3.04%
Fidelity Management & Research Company LLC
1.92%
T. Rowe Price Investment Management, Inc.
1.87%
Other
38.36%
Shareholder Types
Shareholders
Proportion
Corporation
59.74%
Investment Advisor
15.63%
Investment Advisor/Hedge Fund
3.83%
Individual Investor
2.11%
Research Firm
1.19%
Hedge Fund
1.05%
Sovereign Wealth Fund
0.63%
Bank and Trust
0.22%
Pension Fund
0.18%
Other
15.43%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
774
54.93M
21.75%
-6.01M
2025Q3
808
54.84M
25.69%
-1.45M
2025Q2
821
56.21M
24.34%
+2.26M
2025Q1
832
54.17M
23.64%
-2.66M
2024Q4
855
52.85M
22.63%
+3.24M
2024Q3
827
49.68M
20.44%
+4.23M
2024Q2
801
45.24M
20.73%
+361.30K
2024Q1
817
44.34M
21.44%
-6.62M
2023Q4
879
44.00M
20.40%
+3.38M
2023Q3
904
40.73M
20.46%
-291.47K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
AT Impf GmbH
101.85M
40.33%
-636.54K
-0.62%
Dec 31, 2024
Medine GmbH
40.13M
15.89%
-304.48K
-0.75%
Mar 31, 2025
Baillie Gifford & Co.
7.88M
3.12%
-159.51K
-1.98%
Sep 30, 2025
Fidelity Management & Research Company LLC
4.98M
1.97%
-2.00M
-28.65%
Sep 30, 2025
T. Rowe Price Investment Management, Inc.
4.83M
1.91%
+1.24M
+34.32%
Sep 30, 2025
Flossbach von Storch AG
4.23M
1.68%
-65.00
-0.00%
Sep 30, 2025
PRIMECAP Management Company
3.87M
1.53%
-130.70K
-3.27%
Sep 30, 2025
Dodge & Cox
3.65M
1.44%
+2.77M
+315.65%
Sep 30, 2025
Sahin (Ugur MD)
2.05M
0.81%
-724.50K
-26.11%
Mar 31, 2025
Pfizer Inc
1.66M
0.66%
-2.00M
-54.67%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Langar Global HealthTech ETF
4.06%
iShares Genomics Immunology and Healthcare ETF
3.6%
First Trust NYSE Arca Biotechnology Index Fund
3.42%
Global X Genomics & Biotechnology ETF
3.11%
WisdomTree BioRevolution Fund
2.74%
Franklin Genomic Advancements ETF
2.46%
VanEck Biotech ETF
2.38%
Virtus LifeSci Biotech Products ETF
1.58%
ProShares Ultra Nasdaq Biotechnology
1.02%
Invesco Nasdaq Biotechnology ETF
1.01%
View more
Langar Global HealthTech ETF
Proportion4.06%
iShares Genomics Immunology and Healthcare ETF
Proportion3.6%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.42%
Global X Genomics & Biotechnology ETF
Proportion3.11%
WisdomTree BioRevolution Fund
Proportion2.74%
Franklin Genomic Advancements ETF
Proportion2.46%
VanEck Biotech ETF
Proportion2.38%
Virtus LifeSci Biotech Products ETF
Proportion1.58%
ProShares Ultra Nasdaq Biotechnology
Proportion1.02%
Invesco Nasdaq Biotechnology ETF
Proportion1.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Biontech SE?
The top five shareholders of Biontech SE are:
AT Impf GmbH holds 101.85M shares, accounting for 40.33% of the total shares.
Medine GmbH holds 40.13M shares, accounting for 15.89% of the total shares.
Baillie Gifford & Co. holds 7.88M shares, accounting for 3.12% of the total shares.
Fidelity Management & Research Company LLC holds 4.98M shares, accounting for 1.97% of the total shares.
T. Rowe Price Investment Management, Inc. holds 4.83M shares, accounting for 1.91% of the total shares.
AT Impf GmbH holds 101.85M shares, accounting for 40.33% of the total shares.
Medine GmbH holds 40.13M shares, accounting for 15.89% of the total shares.
Baillie Gifford & Co. holds 7.88M shares, accounting for 3.12% of the total shares.
Fidelity Management & Research Company LLC holds 4.98M shares, accounting for 1.97% of the total shares.
T. Rowe Price Investment Management, Inc. holds 4.83M shares, accounting for 1.91% of the total shares.
What are the top three shareholder types of Biontech SE?
The top three shareholder types of Biontech SE are:
AT Impf GmbH
Medine GmbH
Baillie Gifford & Co.
AT Impf GmbH
Medine GmbH
Baillie Gifford & Co.
How many institutions hold shares of Biontech SE (BNTX)?
As of 2025Q4, 774 institutions hold shares of Biontech SE, with a combined market value of approximately 54.93M, accounting for 21.75% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -3.93%.
What is the biggest source of revenue for Biontech SE?
In FY2019, the Collaboration Revenue business generated the highest revenue for Biontech SE, amounting to 84.43M and accounting for 77.75% of total revenue.
